ReviewCurrent pharmaceutical design2012
The redox biology of schistosome parasites and applications for drug development.
Review in Current pharmaceutical design, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Structural basis for substrate recognition and inhibition of thioredoxin glutathione reductase from Schistosoma japonicum: Implications for antiparasitic development.PLoS pathogens · 2026Article
- A genome-scale drug discovery pipeline uncovers therapeutic targets and a unique p97 allosteric binding site inProceedings of the National Academy of Sciences of the United States of America · 2025Article
- A genome-scale drug discovery pipeline uncovers new therapeutic targets and a unique p97 allosteric binding site inbioRxiv : the preprint server for biology · 2025Article
- Neglected Tropical Diseases and Female Infertility: Possible Pathophysiological Mechanisms.Journal of tropical medicine · 2025Review
- Efficacy of Praziquantel in TreatingBiomedicines · 2024Article
- Article
- Beyond schistosomiasis: unraveling co-infections and altered immunity.Clinical microbiology reviews · 2024Review
- Oxidative Stress and Cancer Risk in Schistosomiasis.Oxidative medicine and cellular longevity · 2024Review
- TRP drop, TRP drop: a steady patter of anti-schistosomal target illumination.Frontiers in parasitology · 2024Review
- Natural Perylenequinone Compounds as Potent Inhibitors ofLife (Basel, Switzerland) · 2023Article
- Non-covalent inhibitors of thioredoxin glutathione reductase with schistosomicidal activity in vivo.Nature communications · 2023Article
- Article
- Increased hepatic interleukin-1, arachidonic acid, and reactive oxygen species mediate the protective potential of peptides shared by gut cysteine peptidases against Schistosoma mansoni infection in mice.PLoS neglected tropical diseases · 2023Article
- Comparative metabolic profiling byParasitology research · 2022Article
- Bioorganometallic Compounds as Novel Drug Targets against Schistosomiasis in Sub-Saharan Africa: An alternative to Praziquantel?Advanced pharmaceutical bulletin · 2022Review
- Rhesus macaques self-curing from a schistosome infection can display complete immunity to challenge.Nature communications · 2021Article
- Immunological and Biochemical Interplay between Cytokines, Oxidative Stress and Schistosomiasis.International journal of molecular sciences · 2021Review
- Closing the Gap: An Atomistic Structural and Functional Perspective of S. mansoni Universal Stress G4LZI3 Protein in Complex with Phenolic Compounds.Current drug discovery technologies · 2021Article
- Computationally-guided drug repurposing enables the discovery of kinase targets and inhibitors as new schistosomicidal agents.PLoS computational biology · 2018Article
- Metazoan Parasite Vaccines: Present Status and Future Prospects.Frontiers in cellular and infection microbiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Schistosomiasis caused by Schistosoma spp. is a serious public health concern, especially in sub-Saharan Africa. Praziquantel is the only drug currently administrated to treat this disease. However, praziquantel-resistant parasites have been identified in endemic areas and can be generated in the laboratory. Therefore, it is essential to find new therapeutics. Antioxidants are appealing drug targets. In order to survive in their hosts, schistosomes are challenged by reactive oxygen species from intrinsic and extrinsic sources. Schistosome antioxidant enzymes have been identified as essential proteins and novel drug targets and inhibition of the antioxidant response can lead to parasite death. Because the organization of the redox network in schistosomes is significantly different from that in humans, new drugs are being developed targeting schistosome antioxidants. In this paper the redox biology of schistosomes is discussed and their potential use as drug targets is reviewed. It is hoped that compounds targeting parasite antioxidant responses will become clinically relevant drugs in the near future.
Indexed as
Identifiers
22607149PMC3638776What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.